'Twincretin' Tirzepatide Gets FDA Approval for Type 2 Diabetes

Endocrinologists voice enthusiasm for the first approved agent for patients with type 2 diabetes that is a dual incretin agonist, but they also express concern about cost and patient accessibility. FDA Approvals